API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D agreement between Gilead and DURECT.
Lead Product(s): Sucrose Acetate Isobutyrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Saber
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $23.1 million Upfront Cash: Undisclosed
Deal Type: Termination June 26, 2020